Tissue Factor Pathway Inhibitor and Anitithrombin Trial Results - 18/08/11
, Steven M. Opal, MD bRésumé |
The endogenous plasma anticoagulant proteins tissue factor pathway inhibitor (TFPI) and antithrombin (AT) have both been extensively studied in large, multinational phase III clinical trials in patients with severe sepsis. The TFPI and AT trials failed to result in significant reductions in the 28-day, all-cause mortality rates in their respective study populations. However, there appear to be definable patient populations within each study that may have benefited from TFPI or AT. Drug-drug interactions and dosing issues were observed in both trials. The similarities and differences of each anticoagulant and the lessons learned from the recent phase III clinical trials are examined in this review.
Le texte complet de cet article est disponible en PDF.Plan
| Drs. LaRosa and Opal receive investigator grants and consulting fees from Chiron Corporation, the manufacturer of rTFPI. |
Vol 21 - N° 3
P. 433-448 - juillet 2005 Retour au numéro
Article précédent
- Sepsis and Coagulation
- William C. Aird
- Disseminated Intravascular Coagulation: What's New?
- Marcel Levi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?